{
    "2019-05-15": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Teva Hits Fibonacci Support on Concerns Over Lawsuit",
                "features": {
                    "keywords": [
                        "Teva",
                        "Fibonacci Support",
                        "Concerns",
                        "Lawsuit"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Teva",
                        "Mylan",
                        "Novartis",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-22",
                "original_text": "Novartis gets approval to sell Kymriah in Japan for $306,000",
                "features": {
                    "keywords": [
                        "Novartis",
                        "approval",
                        "Kymriah",
                        "Japan",
                        "$306,000"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}